Chemistry - A European Journal · 2021 · 19 citations · 23 references
MedicineChemistryMedicinal ChemistryNuclear ChemistryRadionuclide TherapyTherapeutic Nuclear MedicineNuclear Medicine ChemistryRadiochemical AnalysisRadioiodine TherapyRadiopharmaceutical PreparationRadiopharmaceutical TherapyRadiopharmaceuticalsAstatine-211 ChemistryDiagnostic RadiopharmaceuticalsIodine-123 ChemistryNucleophilic ReactivityRadiochemical SynthesisRadiolabeling ChemistryRadionuclide LabelingRadiotracer Labeling Chemistry
Abstract Despite the growing interest in radioiodine and 211 At‐labeled radiopharmaceuticals, the search for radiolabeling reactions has been somewhat neglected, resulting in a limited number of available radiosynthetic strategies. Herein we report a comparative study of nucleophilic 125 I and 211 At‐labeling of aryliodonium ylides. Whereas radioiodination efficiency was low, 211 At‐labeling performed efficiently on a broad scope of precursors. The most activated aryliodonium ylides led rapidly to quantitative reactions at room temperature in acetonitrile. For deactivated precursors, heating up to 90 °C in glyme and addition of 2,2,6,6‐tetramethylpiperidine‐1‐oxyl (TEMPO) as radical scavenger appeared essential to avoid precursor degradation and to achieve high radiochemical yields and molar activity. The approach was applied successfully to the preparation of 4‐[ 211 At]astatophenylalanine (4‐APA), an amino acid derivative increasingly studied as radiotherapeutic drug for cancers. This validated aryliodonium ylides as a valuable tool for nucleophilic 211 At‐labeling and will complement the short but now growing list of available astatination reactions.
23
Michael R. Zalutsky, P K Garg, H. S. Friedman et al. · Proceedings of the National Academy of Sciences · 1989 · 153 citations · Full text
Medicine, Nuclear Medicine, Oncology +17